Vyne Therapeutics' Phase 2b Trial of Repibresib Gel in Nonsegmental Vitiligo Misses Primary Endpoint

MT Newswires Live
07-30

Vyne Therapeutics (VYNE) shares were down more than 71% in early Wednesday trading after the company said its phase 2b trial evaluating repibresib gel in nonsegmental vitiligo did not meet its primary endpoint.

The trial also missed a key secondary endpoint and based on the data, Vyne Therapeutics said it will terminate the trial.

Vyne Therapeutics said it plans to seek a development and commercialization partner for repibresib.

Price: 0.41, Change: -1.03, Percent Change: -71.74

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10